In patients with biliary tract cancer with a BRAF mutation, treatment with dabrafenib plus trametinib shrank tumors, results from a phase 2 trial show.
Targeted Treatment for Rare GI Cancers May Extend Survival
Posted in biotech/medical
Posted in biotech/medical
In patients with biliary tract cancer with a BRAF mutation, treatment with dabrafenib plus trametinib shrank tumors, results from a phase 2 trial show.